Analysts Set Abivax SA Sponsored ADR (NASDAQ:ABVX) PT at $134.75

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have been assigned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $134.75.

Several analysts recently commented on ABVX shares. Morgan Stanley increased their target price on shares of Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Oppenheimer set a $131.00 price target on shares of Abivax in a research report on Thursday, January 8th. Guggenheim reiterated a “buy” rating and set a $175.00 price objective on shares of Abivax in a research report on Thursday, December 18th. Citizens Jmp raised their price objective on Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a research note on Tuesday, December 16th. Finally, BTIG Research restated a “buy” rating and issued a $150.00 target price on shares of Abivax in a report on Wednesday, February 25th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE increased its stake in Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after buying an additional 1,990 shares during the period. Cubist Systematic Strategies LLC raised its holdings in shares of Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after acquiring an additional 2,595 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Abivax by 6.0% during the first quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock worth $6,171,000 after acquiring an additional 56,235 shares in the last quarter. Woodline Partners LP boosted its position in Abivax by 319.5% during the first quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock valued at $1,262,000 after purchasing an additional 153,788 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Abivax in the second quarter valued at about $139,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Trading Down 3.0%

Shares of NASDAQ:ABVX opened at $109.33 on Thursday. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. The company’s 50-day moving average price is $121.24 and its 200 day moving average price is $107.57. The company has a market cap of $8.64 billion, a PE ratio of -26.16 and a beta of 1.00. Abivax has a fifty-two week low of $4.77 and a fifty-two week high of $148.83.

Abivax (NASDAQ:ABVX) last posted its earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The company had revenue of ($4.92) million during the quarter. Sell-side analysts anticipate that Abivax will post -2.83 earnings per share for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.